When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALPMF - Audentes reports third fatality in study of gene therapy in rare neuromuscular disorder
Astellas Pharma Inc
Astellas Pharma (OTCPK:ALPMF) unit Audentes Therapeutics reports the third death in its Phase 1/2 ASPIRO study evaluating gene therapy AT132 in patients with X-linked myotubular myopathy, a rare serious and life-threatening inherited disorder characterized by weakness in the skeletal muscles that impairs the development of motor skills such as sitting, standing and walking.
More news on: Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks news,